|
Delphi 3 Responses |
||||
| PROBLEM-TREATMENT |
MEAN |
MEDIAN |
CONFIDENCE INTERVAL AROUND MEDIAN (α = 0.05) |
|
|
|
||||
| Lower Limit |
Upper Limit |
|||
|
|
||||
| Uveitis (JRA, sarcoid, or idiopathic) unresponsive to MTX treated with infliximab |
2.86 |
2 |
1 |
3 |
| Systemic onset JRA treated with anakinra |
3.68 |
3 |
3 |
4 |
| Pediatric SLE treated with MMF |
4.15 |
4 |
3 |
5 |
| JDM unresponsive to prednisone and DMARDS treated with etanercept |
4.59 |
4 |
4 |
6 |
| Systemic onset JRA treated with thalidomide |
4.28 |
5 |
3 |
5 |
| Thrombocytopenia unresponsive to standard therapy in SLE treated with rituximab |
4.57 |
5 |
4 |
5 |
| Localized Scleroderma treated with steroids and MTX |
4.88 |
5 |
4 |
6 |
| Pauci-articular JRA with uveitis, with early treatment |
6.97 |
8 |
8 |
8 |
|
JRA: Juvenile Rheumatoid Arthritis MTX: Methotrexate SLE: Systemic Lupus Erythematosus MMF: Mycophenolate mofetil JDM: Juvenile Dermatomyositis DMARDS: Disease-Modifying Anti-Rheumatic Drugs | ||||
Ota et al. Pediatric Rheumatology 2008 6:5 doi:10.1186/1546-0096-6-5 |
||||